Dactinomycin (actinomycin D) is a chromopeptide antibiotic that intercalates into double-stranded DNA and inhibits RNA polymerase, used in the treatment of paediatric solid tumours including Wilms' tumour, Ewing's sarcoma and rhabdomyosarcoma. Simson Pharma's Dactinomycin reference standard and impurities support precise potency control for this high-potency oncology injectable.
Simson Pharma Global Ltd. (UK) and Simson Pharma Global LLC (USA) supply high-quality Dactinomycin Reference Standards, pharmacopoeial reference materials, and its related impurities to pharmaceutical manufacturers, CROs, analytical laboratories, universities, and regulatory organizations worldwide. To service the Europe and America market efficiently, Simson Pharma Limited has set up Simson Pharma Global Ltd. in United Kingdom and Simson Pharma Global LLC in USA respectively.
